key: cord-0259081-xh1e8f9h authors: Shehab, M.; Alrashed, F.; Alfadhli, A.; Alotaibi, K.; Alsahli, A.; Mohammad, H.; Cherian, P.; Alkhairi, I.; Thanaraj, T. A.; Channanath, A.; Ali, H.; Abu-farha, M.; Abubaker, J.; Al-Mulla, F. title: Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies; A Multi-Center Prospective Study date: 2021-11-01 journal: nan DOI: 10.1101/2021.10.31.21265718 sha: 0116550a4c7206e9ea269737d226425b6bf318a3 doc_id: 259081 cord_uid: xh1e8f9h Introduction Immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologics are not well studied. The goal of this study is to measure serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biologic therapies. Method We performed a multi-center prospective study between August 1st, 2021, and September 15th, 2021. We measured seropositivity of SARS-CoV2 antibodies, SARS-CoV-2 IgG and neutralizing antibody concentrations, in patients with IBD receiving biologic therapies between 4-10 weeks after second dose or 3-6 weeks after first dose of vaccination with BNT162b2 or ChAdOx1 nCoV-19 vaccines. Results There were 126 patients enrolled (mean age, 31 years; 60% male; 71% Crohns disease, 29% ulcerative colitis). 92 patients were vaccinated with BNT162b2 vaccine (73%) and 34 patients with ChAdOx1 nCoV-19 vaccine (27%). The proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving 2 doses of the vaccine in patients treated with infliximab and adalimumab were 44 out of 59 patients (74.5%) and 13 out of 16 patients (81.2%), respectively. Whereas the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine in patients treated with ustekinumab and vedolizumab were 100% and 92.8%, respectively. In patients receiving infliximab and adalimumab, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels after two-dose vaccination was 40 out of 59 patients (67.7%) and 14 out 16 patients (87.5%), respectively. Whereas the proportions of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels were 12 out of 13 patients (92.3%) and 13 out of 14 patients (92.8%) in patients receiving ustekinumab and vedolizumab. Conclusion: The majority of patients with IBD on infliximab, adalimumab, and vedolizumab seroconverted after two doses of SARS-CoV-2 vaccination. All patients on ustekinumab seroconverted after two doses of SARS-CoV-2 vaccine. BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 are both likely to be effective after two doses in patients with IBD on biologics. A follow up larger studies are needed to evaluate if decay of antibodies occurs over time. with Inflammatory Bowel Disease on Biologic Therapies; A Multi-Center Prospective Study Introduction COVID-19 has rapidly become a major health concern worldwide. It is caused by a new virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 To curb the ongoing pandemic caused by SARS-CoV-2 infection, development of vaccines has been advancing at an unprecedented pace, and many countries have authorized different vaccines. BNT162b2 (Pfizer/BioNTech) and the adenovirus-vector vaccine, ChAdOx1 nCoV-19 (Oxford/AstraZeneca) are commonly used worldwide to face further surges of SARS-CoV-2 infection. Both vaccines have demonstrated effectiveness in preventing severe COVID-19 in a phase III placebo-controlled randomized clinical trial and in real-world data. [2] [3] [4] Patients with inflammatory bowel disease (IBD) treated with biologic therapy are considered to be immunocompromised and may be at increased risk of infection. 5, 6 However, in patients with IBD who are receiving biologic therapies, no association was found with severe COVID-19 outcomes such as hospitalization and death. 7 In addition, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) recommends that patients with IBD should be vaccinated against COVID-19 and that vaccination should not be deferred in patients receiving biologic therapy. 8 However, clinical trials excluded patients taking immunosuppressive medications, therefore, it is imperative to evaluate effectiveness of coronavirus disease 2019 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 1, 2021. ; https://doi.org/10.1101/2021. 10 .31.21265718 doi: medRxiv preprint vaccination in patients with IBD with diverse exposure to biologic therapies. Thus, the goal of this study is to determine the immunogenicity of BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD, receiving different biologic therapies. We performed a prospective multi center cohort study at two tertiary care centers (Muabark Alkabeer Hospital and Dasman Center). Patients were recruited at the time of attendance at the gastroenterology infusion rooms and clinics between August 1 st , 2021, and September 15 th , 2021. Our inclusion criteria the following: 1) patients with confirmed diagnosis of inflammatory bowel disease before the start of the study 2) patients receiving tumor necrosis factors antagonists (anti-TNFs), vedolizumab or ustekinumab for at least 6 weeks for induction of remission or before next scheduled dose for patients on maintenance therapy (within dose intervals) 3) have received one or two-dose of COVID-19 vaccination with BNT162b2 or ChAdOx1 nCoV-19 vaccine 4) within 4-10 weeks before recruitment for patients who received two doses of vaccination and within 3-6 weeks for patients who received one dose of vaccination 5) at least are 18 years of age or older. Patients were excluded if they were tested positive SARS-CoV-2 previously or had symptoms of COVID-19 since the start of the pandemic. In addition, patients who received corticosteroids two weeks before the first dose of the vaccine up to the time of recruitment were excluded. Also, patients who missed their scheduled biologic dose were excluded. Finally, patients taking immunomodulators such as azathioprine, methotrexate or other immunosuppressive therapies were also excluded. This study was performed and reported in accordance with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline. 9 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted November 1, 2021. ; https://doi.org/10.1101/2021.10.31.21265718 doi: medRxiv preprint Diagnosis of inflammatory bowel disease (IBD) was made according to the international classification of diseases (ICD-10 version:2016). Patients were considered to have IBD when they had ICD-10 K50, K50.1, K50.8, K50.9 corresponding to Crohn's disease (CD) and ICD-10 K51, k51.0, k51.2, k51.3, k51.5, k51.8, k51.9 corresponding to ulcerative colitis (UC). 10 To evaluate the serological response to BNT162b2 or ChAdOx1 nCoV-19 vaccine in patients with IBD on biologic therapies, we measured levels of SARS-CoV-2 Immunoglobulin G (IgG) and neutralizing antibodies post vaccination. In addition, we calculated the percentage of patients who achieved positive SARS-CoV-2 antibodies levels. We performed descriptive statistics to present the demographic characteristics of patients included in this study and their measured antibody levels. Analysis was conducted using R (R Core Team, 2017). SARS-CoV-2 antibody levels are expressed as medians with interquartile range (IQR) unless otherwise indicated. In addition, percentages of positive IgG and neutralizing antibody levels post vaccination were calculated per each biologic (infliximab, adalimumab, vedolizumab, and ustekinumab). In this study, anti-SARS-CoV-2 antibodies quantification from plasma to assess magnitude of systemic virus specific antibodies was performed using enzyme-linked immunosorbent assay The study included 126 participants, mean age was 31 years and 60% were males. Mean BMI was 25 kg/m 2 . The proportion of patients with Crohn's disease and ulcerative colitis was 71% and 29% respectively. (see table 1) In terms of biologic therapies, 78 (62%) patients were on infliximab and 18 (14%) patients were on adalimumab, whereas the number of patients receiving vedolizumab or ustekinumab was similar at 15 (12%). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 1, 2021. were on infliximab, 2 patients were on adalimumab, 2 were on ustekinumab, and 1 was on vedolizumab. In patients receiving infliximab, 14 out of 19 (73.6%) had positive anti-SARS-CoV-2 IgG and neutralizing antibody levels. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 1, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 1, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 1, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 1, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 1, 2021. Our findings showing seroconversion across medication groups are consistent with other IBD studies. One study 12 assessed humoral responses after mRNA vaccination in adults with IBD at different time points. The study found that regardless of medication regimen, 99% of participants had detectable antibodies after 2 weeks. In addition, anti-SARS-CoV-2 IgG levels were lowest in patients receiving anti-tumor necrosis factor combination therapy or corticosteroids. However, it is important to mention that the study was not powered to assess differences between medication subgroups. Khan et al explored the effectiveness of mRNA vaccination in the veterans patients with IBD receiving diverse immunosuppressive medications. 13 The authors observed that two doses of mRNA vaccine, but not a single dose, was associated with 69% reduced hazard of infection relative . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 1, 2021. to an unvaccinated status. They also suggested that SARS-CoV-2 vaccine effectiveness is similar in patients with IBD regardless of the immunosuppressive agents being used. Wong et al reported serological responses to mRNA vaccination in patients with IBD on biologic therapies. 14 They found that despite achieving antibody levels consistent with presumed protection, there was an association of lower antibody levels in patients with vedolizumab for all antibodies tested and with anti-TNFs for the receptor binding domain (RBD) of the SARS-CoV-2 S protein total immunoglobulin. One study 15 reported the effectiveness of the BNT162b2 mRNA COVID-19 vaccine in patients with IBD receiving different therapies including biologic. The authors found that in patients with IBD, the vaccine was highly effective and comparable to the general population with an absolute breakthrough infection rate of 0.1% for fully vaccinate IBD patients. However, the study suggested that patients with Crohn's disease (CD) may have an increased risk for breakthrough infection, but larger studies are needed to validate this finding. Anti-SARS-CoV-2 circulating antibodies play a major role in risk reduction of severe COVID-19. IgG class particularly target the spike protein of SARS-CoV-2, its S1 subunit or its receptor binding domain (RBD). 16 Thus, the binding of the virus to host receptors is weakened or terminated completely. Neutralizing antibodies are major contributors to immunity. 17, 18 Vaccine studies showed that high levels of IgG and neutralizing antibodies against the SARS-CoV-2 spike protein correlate with protection. However, it is not currently known what the threshold titers should be to achieve protection. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted November 1, 2021. ; https://doi.org/10.1101/2021.10.31.21265718 doi: medRxiv preprint CLARITY IBD study 19 showed that the lowest rates of seroconversion were observed in participants treated with infliximab in combination with an immunomodulator with both the BNT162b2 or ChAdOx1 nCoV-19 vaccines. Interestingly, highest rates of seroconversion were seen in patients treated with vedolizumab monotherapy who received either one of the previously mentioned vaccines. Anti-TNF agents inactivate the proinflammatory cytokine TNF by direct neutralization, thus resulting in suppression of inflammation. The cytokine TNF is involved in multiple aspects of host immune responses, including T-cell dependent antibody production. This mechanism of action may in part explain why TNF blockade is clinically beneficial, but also explain the increased risk of serious and opportunistic infections and impaired response to some vaccines. 20 The mechanism of action of vedolizumab , an anti-integrin, is hypothesized to be restricted to the gastrointestinal tract, not affecting immune responses outside of the gastrointestinal tract. 21 Finally, ustekinumab inhibit the p40 subunit of interleukin (IL)-12/23, which are major drivers of the adaptive immune response. 22 Taken together, these emerging data provide reassurance that biologic therapies do not markedly reduce the response to COVID-19 immunization and support recent consensus recommendations to vaccinate all patients with IBD regardless of immune-modifying therapies. 23 However, patients should be advised that vaccine efficacy may be decreased when receiving systemic corticosteroids. In addition, anti-SARS-CoV2 antibodies decay remains a legitimate concern in patients with IBD . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted November 1, 2021. ; https://doi.org/10.1101/2021.10.31.21265718 doi: medRxiv preprint on biologic therapy, 24 therefore, booster doses are being recommended by official organizations. 25, 26 Our study has several strengths. It is a multi-center prospective study. It examined the effect of two important SARS-CoV-2 vaccines in a vulnerable patient population with IBD on common biologic agents, who might be reluctant to vaccinate. It is well designed with low risk of bias given its inclusion and exclusion criteria. It addresses a very clinically relevant question that physicians and patients are eager to know. However, our study has some limitations. It includes a small sample size of patients, so it was not powered to assess differences across medication subgroups. Furthermore, only humoral serological responses were assessed, it is likely that T cell-mediated immunity plays a possible protective role. Finally, given the observational nature of the study, possible confounders may exist, such as difference in biologic dosing and serum drug concentrations were not accounted for. A follow up larger studies needed to evaluate if decay of antibodies occurs over time and if a possible third booster vaccine dose may be needed. To conclude, this study showed that most patients with IBD on infliximab, adalimumab, and vedolizumab seroconverted after two doses of SARS-CoV-2 vaccination. All patients on ustekinumab seroconverted after two doses of SARS-CoV-2 vaccine. BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 are both likely to be effective after two doses in patients with IBD on . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted November 1, 2021. ; https://doi.org/10.1101/2021.10.31.21265718 doi: medRxiv preprint CDC. Human Coronavirus Types. COVID-19 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses Serious infection and mortality in patients with crohn's disease: More than 5 years of follow-up in the TREAT registry Aline Charabaty MS. The Impact of Systematic Review and Meta-analysis Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies ICD-10 : international statistical classification of diseases and related health problems : tenth revision Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 Antibody Responses After SARS-CoV-2 mRNA Vaccination in in Adults With Inflammatory Bowel Disease Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications Serologic Response to Messenger RNA . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign Anti-spike s1 iga, anti-spike trimeric igg, and anti-spike rbd igg response after bnt162b2 covid-19 mrna vaccination in healthcare workers Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Neutralizing antibodies targeting SARS-CoV-2 spike protein Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD Molecular mechanism of action of antitumor necrosis factor antibodies in inflammatory bowel diseases Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: Randomised controlled trial results Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: Recommendations from an international consensus meeting Covid-19 Vaccine-Induced Antibodies Are Attenuated and Decay Rapidly in Infliximab Treated Patients FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations. Food and Drug Administration BSG Inflammatory Bowel Disease Section and Clinical Research Group position statement on SARS-CoV2 Vaccination | The British Society of Gastroenterology